Abstract:Breakthroughs in biotechnology, globalizing intellectual property rights legislations, and growing venture capital in the past thirty years have given rise to new forms of capitalist accumulation that scholars called biocapitalism. Bioscientific knowledge under biocapitalism is increasingly parceled out from a global common to private enclosures for biotech and pharmaceutical companies, contributing to vast inequalities and fractures of global access to innovation evident in the COVID-19 pandemic. The assetization and financialization of knowledge have shifted the ground of innovation from competitive commodity production and exchanges to generating, managing, and commercializing patents and associated monopoly rights, thus raising the challenges of innovation for those developing countries specialized in production. Many Asian countries have invested heavily in biomedical sciences to enhance their knowledge assets but had limited success in translating the scientific development to a globally significant biomedical industry. This article discusses the evolution of China's biomedical industry from a technological laggard to a recent innovation boom after a regulatory overhaul in 2015. Analyzing the patent collaborative networks of China's biomedical industry since 2003, we found the central roles of domestic public research institutions, in contrast to multinational corporations, as cutting-edge knowledge providers. We argue that China's path of the biomedical industry is distinct from its other technology industries that rely on multinational corporations for core knowledge. It represents a national articulation in response to global biocapitalism by situating the domestic research institutions and biomedical firms at the center of knowledge assets production and engaging globally in the science and drug regulatory systems.

Intellectual Property and Funding: Fueling Chinese Synbio

Legal Protection of China's Biotechnology Patents

Synthetic Biology and Governance Research in China: a 40-Year Evolution

Creating Knowledge Assets under Biocapitalism: Analyzing China's Biomedical Industry and Its Patent Networks

Pharmaceutical corporate power, traditional medical knowledge, and intellectual property governance in China

[Synthetic biology: from "build-for-use" to commercialization]

Research on Intellectual Property Right Protection of Genetic Resources in China Under Benefit-Sharing

Regulation and management of the biosecurity for synthetic biology

Biosimilar monoclonal antibodies in China: A patent review

Human Research Capacity in Chinese Agbiotech

The Protection and Utilization of Transgenic Intellectual Property Rights in China:Problems and Suggestions

Strategizing Intellectual Property Rights for Enhanced Innovation: the Moderating Effects of R&D and FDI in China's Regional Context

The Evolution of China's IPR System and Its Impact on the Patenting Behaviours and Strategies of Multinationals in China.

International Negotiations on Synthetic Biology and China’s Implementation Strategies Within the Convention on Biological Diversity Framework

The Limits to Law: How Intellectual Properties Are Used and Protected in Chinese Industries

Collaborative R&D: intellectual property rights between Tsinghua University and multinational companies

The International Protection of Intellectual Property Rights and the Challenges China is Confronted With

Enabling Technology and Core Theory of Synthetic Biology

Synthetic biology: a new frontier in food production

Understanding the protecting intellectual property right in the laboratories of the Chinese researching and opening Universities

Patents and China's Research and Development in Agricultural Biotechnology